Uniting Medically Supervised Injecting Centre

Knight to Present at the 2022 BIO International Convention in San Diego

Retrieved on: 
Tuesday, June 7, 2022
Laboratorio de Energía Solar Termoeléctrica, Annual report, BIO, Nature, GUD, Therapy, GLOBE, TSX, Industry, Intention, Biotechnology Innovation Organization, Fine chemical, Uniting Medically Supervised Injecting Centre

MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.

Key Points: 
  • MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.
  • The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the worlds largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight to Present at the Jefferies 2022 Healthcare Conference in New York City

Retrieved on: 
Friday, June 3, 2022
Conference, Laboratorio museotecnico Goppion, Pan-American, Annual report, Nature, GUD, Therapy, GLOBE, TSX, Intention, Generic drug, Uniting Medically Supervised Injecting Centre

MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City.

Key Points: 
  • MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia

Retrieved on: 
Wednesday, June 1, 2022
Laboratorio museotecnico Goppion, Marketing, Annual report, Nature, GUD, Rivastigmine, Parkinson's disease, Therapy, GLOBE, Acquisition, TSX, Dementia, Alzheimer's disease, Intention, Pharmaceutical industry, Uniting Medically Supervised Injecting Centre, Knight, Exelon, Novartis

MONTREAL, June 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon (rivastigmine) in Colombia upon successful transfer of the marketing authorization.

Key Points: 
  • MONTREAL, June 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon (rivastigmine) in Colombia upon successful transfer of the marketing authorization.
  • Exelon is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries.
  • "We are excited to assume full commercial activities of Exelon in Colombia and continue to support this well established and important therapy option in an area of such high unmet need as Alzheimer's," said Samira Sakhia, President & Chief Executive Officer of Knight.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

Retrieved on: 
Tuesday, May 24, 2022
People, CLR, Severe acute respiratory syndrome coronavirus 2, Platelet, Risk, Death, Shock, Organ dysfunction, Autoimmune hemolytic anemia, Thermoregulation, Waiha, Patient, Common, Antibody, Macrovascular disease, GUD, AIHA, Endothelial dysfunction, Therapy, Macrophage, Nature, COVID-19, Jean-Louis Vincent, TSX, Bruise, Intention, Infection, Partnership, Bleeding, ITP, SYK, Splenectomy, Pathology, Neutrophil extracellular traps, Acute kidney injury, Neutrophil, NETS, Monocyte, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), Immune system, Steroid, Knight Therapeutics, Fostamatinib, CEO, Annual report, GLOBE, Pharmaceutical industry, Vaccine, Generic drug, Rigel, Uniting Medically Supervised Injecting Centre, Knight

MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Key Points: 
  • MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • In return, Knight receives exclusive rights to fostamatinib in all potential indications, including chronic ITP, wAIHA, and COVID-19 in Latin America.
  • We are excited to be working with Rigel to provide access to an innovative, first-in-class treatment option to patients across Latin America with chronic ITP.
  • TAVALISSE and TAVLESSE are registered trademarks of Rigel Pharmaceuticals, Inc.
    Investor Contact for Knight Therapeutics Inc.:

VERTESS Completes Three Acquisitions in Q1 2022

Retrieved on: 
Wednesday, May 18, 2022
Multimedia, UMP, Renting, Community Support Group, Uniting Medically Supervised Injecting Centre, Appetite, United States Public Health Service, Pathway, Acquisition, LLC, Hospital, Medicine

FORT WORTH, Texas, May 18, 2022 /PRNewswire/ -- VERTESS, a leading healthcare mergers and acquisitions (M&A) advisory firm, closed out a strong first quarter of 2022 with three transactions.

Key Points: 
  • FORT WORTH, Texas, May 18, 2022 /PRNewswire/ -- VERTESS, a leading healthcare mergers and acquisitions (M&A) advisory firm, closed out a strong first quarter of 2022 with three transactions.
  • Managing Partner Bradley Smith commented that these were noteworthy successes given the current status of the economy and the geopolitical instability overseas.
  • Brannons Rental and Sales, Inc., a California home medical equipment company was acquired by Adapt Medical, a national home medical equipment company.
  • Robert Villalobos, Managing Director and deal lead, noted, "Brannons Medical was a staple in the San Jose community for 20+ years.

Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®

Retrieved on: 
Thursday, May 12, 2022
Nausea, Ageing, NCCN, Environment, Patient, Respect, Palonosetron, GUD, Therapy, Nature, TSX, Intention, Cisplatin, Product, Vomiting, Heart, National Comprehensive Cancer Network, Museo-laboratorio della Civiltà Contadina (Museum-workshop of the Peasant Culture), Corporation, Dexamethasone, Cancer, Growth, GLOBE, CEO, Annual report, Pharmaceutical industry, Platinum, Generic drug, IQVIA, Uniting Medically Supervised Injecting Centre, Knight

Under the terms of the agreement, Knight shall have the exclusive right to distribute, promote, market and sell the Products in the licensed territories.

Key Points: 
  • Under the terms of the agreement, Knight shall have the exclusive right to distribute, promote, market and sell the Products in the licensed territories.
  • We are very excited to enter into this agreement with Helsinn for AKYNZEO in Canada, Brazil and other selected Latin American countries, and ALOXI in Canada, said Samira Sakhia, President and CEO of Knight.
  • AKYNZEO and ALOXI are leading, guideline-recommended1,2,3 antiemetics that help to prevent one of the most common side effects of chemotherapy.
  • AKYNZEO and ALOXI form a key part of Helsinns commercial engine of supportive cancer care products, said Giorgio Calderari, Helsinn CEO.

Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New York City

Retrieved on: 
Thursday, May 12, 2022
InterContinental New York Barclay Hotel, GUD, Therapy, Nature, TSX, Intention, Conference, Laboratorio museotecnico Goppion, Annual report, GLOBE, Uniting Medically Supervised Injecting Centre

MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 at 8:30 am ET at the InterContinental New York Barclay hotel in New York City.

Key Points: 
  • MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022 at 8:30 am ET at the InterContinental New York Barclay hotel in New York City.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Knight Therapeutics Inc. announces voting results from the Annual Meeting

Retrieved on: 
Thursday, May 12, 2022
TSX, Intention, GUD, Laboratorio museotecnico Goppion, Therapy, Nature, Annual report, Generic drug, Security (finance), Pharmaceutical industry, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.

Key Points: 
  • Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call

Retrieved on: 
Thursday, May 5, 2022
GUD, Annual report, TSX, Laboratorio museotecnico Goppion, Nature, Therapy, Intention, Uniting Medically Supervised Injecting Centre

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Knight to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Monday, April 25, 2022
Metro Toronto Convention Centre, GUD, Intention, Annual report, GLOBE, Conference, TSX, Laboratorio museotecnico Goppion, Therapy, Nature, Pharmaceutical industry, Uniting Medically Supervised Injecting Centre

MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (Knight), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 10:30 a.m.

Key Points: 
  • MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (Knight), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 10:30 a.m.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.